|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The p15 and p16 genes are known to be juxtaposed on chromosome 9p21 at the locus of a putative tumour-suppressor gene involved in the initiation of bladder cancer.
|
7577470 |
1995 |
|
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Our results corroborate the earlier findings that single base mutation is not the prime mode of inactivation of the CDKN2A gene in bladder cancer.
|
12532425 |
2003 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer.
|
15987713 |
2006 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
These figures support the use of methylated p16(INK4a) as a new class of tumour marker in bladder cancer.
|
12477660 |
2002 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
At the 9p arm is located the p16 (MTS1) TSG and probably others with an effect on various human tumours such as acute lymphoblastic leukaemia, bladder cancer, gliomas, malignant mesotheliomas, melanomas and non-small cell lung carcinomas.
|
7585472 |
1995 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.
|
8747595 |
1995 |
|
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
p14 hypermethylation could be involved in early stage of bladder carcinogenesis, and p14 hypermethylation in pathologically normal urothelium samples should be considered a predictor of bladder cancer recurrence.
|
20800513 |
2012 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study, the efficacy of mouse p16 peptide administration in a mouse lung metastasis model for BT and also the toxicity of peptides by cardiac peptide injection were evaluated.
|
30655885 |
2019 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using methylation-specific PCR (MSP), we examined the methylation status of p16(INK4a) and p14(ARF) in 64 samples from 45 bladder cancer patients (34 males, 11 females).
|
16316628 |
2006 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
We, therefore, examined, in a population-based study of human bladder cancer (n = 351), the relationship between epigenetic silencing of the tumor-suppressor genes, p16(INK4A), RASSF1A, PRSS3, and the four SFRP genes and exposure to both tobacco and arsenic in bladder cancer.
|
17119258 |
2006 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
We conclude that p16 represents the major target for deletion at 9p21 in bladder cancer.
|
8541841 |
1995 |
|
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Of the entire group, p15 and p16 alteration and positive TGF-alpha (> or =cutoff value) were significantly expressed in schistosomal bladder cancer (68.1%, 60.9%, and 65.2%), and squamous cell carcinoma type (SCC) (69.1%, 64.7% and 72.1%) compared to those with non-schistosomal bladder cancer (29.4%, 7.8%, and 37.3%) or transitional cell carcinoma (TCC) (28.8%, 3.8%, and 28.8), respectively.
|
15589816 |
2004 |
|
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Effects of exogenous wild-type P16 gene transfection on the expression of cell cycle-related proteins in bladder cancer cell line.
|
16100943 |
2005 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we applied gene-specific probes for CDKN2 and the interferon alpha gene (IFNA), also located at 9p21, to characterize further the genomic deletions at this locus in bladder cancer.
|
9171998 |
1997 |
|
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Our data show a significant correlation (P = 0.00001, two-sided) between the absence of p16/CDKN2 expression and methylation of its 5' CpG island in bladder tumors, cell lines, and normal colon mucosa.
|
7553622 |
1995 |
|
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, deletions and methylation of the INK4A gene occur frequently in superficial bladder tumors.
|
10393843 |
1999 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
We identified a miR-877-3p binding site on the promoter site of tumor suppressor gene p16 which alters frequently in bladder cancer.
|
27429046 |
2016 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, the systemic peptide delivery of p16 restores the hypophosphorylation of pRb and may be a useful tool for the treatment of bladder tumors.
|
23292502 |
2013 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These observations as well as the observation that bladder cancer is associated with deletions of CDKN2, a gene important in normal senescence, led us to examine normal urothelial cell response to H2O2.
|
10938379 |
2000 |
|
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Detection of human papillomavirus infection and p16 immunohistochemistry expression in bladder cancer with squamous differentiation.
|
24675970 |
2014 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Collectively, we provided evidence that Jarid2 via modulation of p16 is a putative novel therapeutic target for treating malignant bladder cancer.
|
28445934 |
2017 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, DE-miRNAs in bladder cancer tissue samples and DE-targeted genes, such as miR-106b and CDKN2A, which were identified in the present study, may provide the basis for targeted therapy for breast cancer and enhance understanding of its pathogenesis.
|
25955758 |
2015 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ASSET analyses identified four SNPs significantly associated with multiple cancers: rs3731239 (CDKN2A intronic) with ESCC, GC and BC (P = 3.96 × 10(-) (4)); rs10811474 (3' of IFNW1) with RCC and BrC (P = 0.001); rs12683422 (LINGO2 intronic) with RCC and BC (P = 5.93 × 10(-) (4)) and rs10511729 (3' of ELAVL2) with LC and BrC (P = 8.63 × 10(-) (4)).
|
25239644 |
2014 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
|
30446453 |
2019 |
|
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
|
9850064 |
1998 |